Mabylon AG Secures CHF 1.3 Million for ALS and Inflammatory Research
Mabylon AG Secures Critical Funding for Innovative Therapies
Mabylon AG, a prominent player in the biotechnology sector specializing in human-derived antibodies, recently announced its remarkable achievement of securing three research grants totaling over CHF 1.3 million. This funding has been designated for its programs focused on amyotrophic lateral sclerosis (ALS) and inflammasome-targeting therapies. These developments reveal a commitment to pushing the boundaries of medical research and treatment.
Focus on Amyotrophic Lateral Sclerosis
The lucrative grants include significant contributions from entities like the Innosuisse Swiss Innovation Agency, Target ALS, and the ALS Association. The funding is focused specifically on advancing the development of TDP-43 intrabodies, which are designed to restore the normal functions of TDP-43 in ALS patients. There is a critical need for effective treatments as TDP-43 aggregates are instrumental in the progression of ALS.
The Importance of TDP-43
TDP-43 has been recognized as a pivotal target in the fight against ALS, affecting both familial and sporadic forms of the disease. Kuldip Dave, Ph.D., Senior Vice President of Research at the ALS Association, expressed optimism regarding the funding's impact on preclinical development efforts, indicating that making rapid progress in treatment options is paramount in managing ALS.
Advances in Inflammatory Bowel Disease Treatment
Aside from its ALS initiatives, Mabylon is also channeling CHF 0.8 million from Innosuisse into its ongoing MY012 program. This innovative antiviral therapy focuses on treating inflammatory bowel disease (IBD) and is designed to enhance both safety and efficacy in patient treatment.
Innovative Approaches to Safe Treatments
Mabylon’s strategy involves identifying naturally occurring antibodies from extensive patient populations or immunized animals. This groundbreaking approach sets the foundation for uncovering promising antibody candidates in ALS and IBD. According to Niccolò Pengo, PhD, Mabylon’s Chief Scientific Officer (CSO), these grants affirm the validity of their research and underscore the therapeutic potential of their discoveries. The funding provides an opportunity to expedite their research programs and assist in future fundraising efforts.
Vision for the Future
Alcide Barberis, PhD, CEO of Mabylon, expressed heartfelt gratitude for the grants, which will support their efforts to reach preclinical proof-of-concept. The goal is to foster partnerships with biopharmaceutical companies or potentially launch a dedicated spinoff to facilitate investments. With a keen focus on developing their innovative anti-allergen antibody candidates, the company is poised for growth and expansion.
Recent Collaborations and Developments
In recent months, Mabylon has made significant strides in its anti-allergen therapies, particularly with a multi-specific anti-allergen antibody currently undergoing Investigative New Drug (IND) studies. This project aims to deliver critical treatments for peanut allergies. Notably, Mabylon has partnered with Pfizer via the Pfizer Ignite program to propel its allergy treatment initiatives forward.
About Mabylon AG
Mabylon AG is a Swiss biotechnology firm dedicated to leveraging the therapeutic capabilities of naturally occurring human antibodies to address allergies, neurodegenerative diseases, and inflammatory conditions. By focusing on antibodies derived from allergic patients, Mabylon's research is enhancing the understanding of allergenic epitopes and their implications in disease progression.
Frequently Asked Questions
What grants has Mabylon AG received?
Mabylon AG has received over CHF 1.3 million in research grants focused on ALS and inflammatory diseases.
How is the funding benefiting ALS research?
The funding is allocated towards developing TDP-43 intrabodies, aimed at restoring normal TDP-43 function in ALS patients.
What is the MY012 program?
The MY012 program targets inflammatory bowel disease, utilizing a proprietary antibody therapy designed for enhanced safety and effectiveness.
What collaborations does Mabylon have?
Mabylon has entered a collaboration with Pfizer for its allergy program through the Pfizer Ignite initiative.
What is Mabylon AG's primary focus?
Mabylon AG focuses on harnessing naturally occurring human antibodies to innovate treatments for allergies, neurodegenerative diseases, and inflammatory conditions.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Market Rally Fueled by Stimulus from China and Japan
- Municipality Finance Launches EUR 50 Million Note Offer
- Nexstim Expands Its Footprint in Finland with New Order
- Nykredit Realkredit A/S Finalizes Terms for New Note Issuance
- Wolters Kluwer Introduces CCH iFirm Validate for Efficient Audits
- Van Leeuwen Pipe and Tube Group Receives Royal Honor for 100 Years
- Sineng Electric Makes Major Leap in U.S. Energy Storage
- Exploring Kamala Harris' Vision for a Fairer Economy
- VINCI Secures Major Highway Concession Amid Infrastructure Growth
- Shigeru Ishiba's Vision for a Resilient Japan Ahead
Recent Articles
- Bed Head Panel Market Expected to Reach $4.3 Billion by 2032
- Results from the Recent Auction of Riksbank Certificate
- Eviden Partners with CFL for Advanced Railway Communication Systems
- Eviden Partners with RATP for Advanced Radio Solutions
- Join SkiStar AB's Conference Call for Year-End Insights
- Semtech Unveils New Solutions for Smart Home Networks
- Eurofins Sustainability Services Unveils Deforestation Assessment
- University of Manchester Enhances Cybersecurity with Tanium
- Mars Partners with Major Logistics Firms for Sustainability
- Aptadir Therapeutics Unveils Innovative RNA-Based Cancer Solutions
- Bio-Sourcing's EIC Accelerator Funding: A Game-Changer for Biopharma
- RWS Enhances Collaboration With AWS for AI Innovations
- Kia's Latest OTA Update: Enhancing EV Experience and Music
- François Garaude's Exceptional Achievements in the Gemstone Industry
- Kia Unveils Exciting OTA Update with SoundCloud Streaming
- EcoCharge and Balancell Join Forces to Boost Africa's Energy Efficiency
- LG's Global Heat Pump Consortium Aims to Revolutionize HVAC
- CDPQ to Enhancement UK Energy Sector with First Hydro Stake
- Zevra Therapeutics Positioned for Growth After MIPLYFFA Approval
- McKesson Faces Analyst Downgrade Amidst Earnings Concerns
- Kepler Cheuvreux Adjusts Aker BP Stock Target Amid Oil Trends
- Goldman Sachs Initiates Buy on Avidity Biosciences Stock
- Barclays Upgrades Saint Gobain's Stock with New Price Target
- JPMorgan Upgrades OMV: A Prime Midcap Investment Opportunity
- BofA Cuts Saab Stock Rating Due to Slowing Growth Expectations
- European Stocks Surge as China Stimulus Boosts Luxury Sector
- Small-Cap Stocks Gain Momentum Following Fed Rate Cut
- Exploring the Impacts of Fed Decisions on Bull Market Trends
- Insider Trading Highlights Recent Investments in Biotech and Energy
- West Red Lake Gold Announces Significant Drill Results at Madsen
- Samsung Unveils Advanced Automotive SSD for AI Applications
- Croesus and Indigita Join Forces for Tax-Efficient Solutions
- South Korea's Bold Military Response to Balloon Disruptions
- Veltassa® Receives Marketing Approval for Hyperkalemia in Japan
- U.S. Market Reaches New Highs Amid Optimism Despite Caution
- Türkiye Launches Ambitious New Notes and Tender Offer Strategy
- Huawei Invites Partners to Enhance Global Digital Inclusion Efforts
- Globe Teleservices Celebrates Major Wins at Antonio Meucci Awards
- Catalent's Buyout Journey: Stock Analysis and Insights Ahead
- Market Movements: Fed Insights and Boeing's Latest Offer
- Levi Strauss Aims for $10 Billion Sales Goal Amid Challenges
- Leapmotor and Stellantis Launch Affordable EVs in Europe
- Bitcoin Struggles to Maintain Momentum as Market Awaits Fed Insights
- Understanding the Stability of Home Prices in Today's Market
- Innovative Insights on Green Hydrogen From NewHydrogen Leaders
- Understanding Riksbank Certificates: Key Auction Details Explained
- CloudInteract Welcomes New Talent for Growth and Expansion
- Veltassa® Receives Approval in Japan to Combat Hyperkalemia
- Veltassa® Receives Approval in Japan for Potassium Control
- REPT BATTERO Expands Global Reach with New U.S. Office